Search results
Obsidian’s Avowed Gets New Story Trailer, Still No Release Date - Xbox Games Showcase 2024
IGN Videogames· 5 days ago"Explore the Living Lands, a mysterious island filled with adventure and danger," Avowed's story...
How Cinnamon Can Benefit Your Health
Mercola· 3 days agoMaharishi Ayurveda Products International (MAPI) notes that cinnamon is often used for Ayurvedic recipes to enhance the bioavailability of other herbs while combining a delicious mixture of ...
10 Best Supplements to Take in the Summer, Doctors Say — Best Life
Best Life· 6 days agoFor instance, as the summer brings excessive heat and damaging UV rays, you can assume your skin,...
This Root Vegetable Helps with Blood Pressure and Inflammation, According to a Dietician
Verywell Health via Yahoo News· 3 days agoThere are many health benefits of beets, but they may not be right for you if you have kidney...
ASCO: AffyImmune builds up foundations of autologous CAR T cell therapy
BioPharma-Reporter· 3 days agoThe US firm AffyImmune Therapeutics discusses how its donor cell-derived candidate could address...
Dominari Holdings Inc. (NASDAQ:DOMH) Short Interest Up 191.7% in May
ETF DAILY NEWS· 2 days agoDominari Holdings Inc. (NASDAQ:DOMH – Get Free Report) was the target of a large increase in short interest during the month of May. As of May 31st, there was short interest totalling 3,500 ...
Ruvidar(TM) Enhances Efficacy of Cancer Drug
The Joplin Globe· 5 days agoTORONTO, ON / ACCESSWIRE / June 10, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research ...
Ruvidar(TM) Enhances Efficacy of Cancer Drug
Digital Journal· 5 days agoTORONTO, ON / ACCESSWIRE / June 10, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 5 days agoJ INTS BIO, ASCO 2024 - JIN-A02 showed tumor reductions including brain metastasis in the ongoing first-in-human, dose-finding Phase 1 clinical study PR Newswire SEOUL, South Korea, June 10, 2024 SEOUL, South Korea, June 10, 2024 /PRNewswire/ --